| Next 10 |
Ad
CNTB News and Press Connect Biopharma Holdings Limited
News | Connect Biopharma Holdings Limited (NASDAQ:CNTB)
-
2023-12-01 08:25:56 ET Losers: Smart for Life ( SMFL ) -38% announces exercise of warrants for $1.5 Million gross proceeds . Ampio Pharmaceuticals ( AMPE ) -34% . Incannex Healthcare ( IXHL ) -34% . Vivos Therapeutics ( VVOS ) -14% . ...
-
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and it...
-
2023-11-26 02:40:00 ET Summary BeiGene acquires global rights to a preclinical CDK2 inhibitor from Ensem Therapeutics in a $1.3 billion agreement. Shanghai Usynova Biopharma out-licenses global rights for its KRASG12D inhibitor to AstraZeneca in a deal worth up to $419 million. ...
-
2023-11-23 03:09:21 ET More on Connect Biopharma Connect Biopharma stock rises on positive data from dermatitis mAb Connect Biopharma receives Nasdaq notification regarding minimum bid price deficiency Financial information for Connect Biopharma For further d...
-
2023-11-22 08:39:27 ET SciSparc ( SPRC ) +24% set to merge with a vehicle importer firm in Israel. Bright Minds Biosciences ( DRUG ) +19% . Grom Social Enterprises ( GROM ) +10% signs $8M convertible notes financing agreement. Connect Biopharm...
-
2023-11-21 06:27:03 ET Connect Biopharma ( NASDAQ: CNTB ) shares jumped 28% premarket on Tuesday after the biopharmaceutical company reported positive long-term data from a trial evaluating its rademikibart drug candidate in patients with moderate-to-severe atopic dermatitis...
-
Simcere has been granted an exclusive right to develop, manufacture, and commercialize rademikibart for all indications in Greater China Connect Biopharma retains rights to develop and commercialize rademikibart in all other markets and completed the pivotal atopic dermatitis (AD) trial in ...
-
Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and every four weeks (Q4W) dosing regimens Approximately 90% of patients on Q4W dose maintained both IGA 0/1 and EASI-75 through Week 52 ...
-
SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inf...
-
2023-11-17 12:41:25 ET Gainers: Altamira Therapeutics Ltd ( CYTO ) +255% . Safe and Green Development Corp ( SGD ) +89% . Fortress Biotech ( FBIO ) +50% . Mural Oncology Plc ( MURA ) +40% . Syntec Optics Holdings ( OPTX ) +35% . ...
Stock Information
Get CNTB Alerts
News, Short Squeeze, Breakout and More Instantly...
Connect Biopharma Holdings Limited Company Name:
CNTB Stock Symbol:
NASDAQ Market:
Ad
-
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and it...
-
Shares of Urban Outfitters, Inc. (NASDAQ: URBN) dipped during Wednesday’s session after the company reported third-quarter financial results....
-
Shares of Guess?, Inc. (NYSE: GES) shares dipped in pre-market trading after the company reported worse-than-expected third-quarter financial res...